T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. The company is headquartered in Lexington, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2014-08-07. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The firm's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. The company also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.
Follow-Up Questions
¿Quién es el CEO de T2 Biosystems Inc?
Mr. Craig Jalbert es el President de T2 Biosystems Inc, se unió a la empresa desde 2025.
¿Qué tal es el rendimiento del precio de la acción TTOO?
El precio actual de TTOO es de $0.012, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de T2 Biosystems Inc?
T2 Biosystems Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de T2 Biosystems Inc?
La capitalización bursátil actual de T2 Biosystems Inc es $336.6K
¿Es T2 Biosystems Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para T2 Biosystems Inc, incluyendo 0 fuerte compra, 0 compra, 3 mantener, 1 venta, y 0 fuerte venta
